FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction

- Designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with preserved ejection fraction RIDGEFIELD, Conn.